Literature DB >> 15946580

Unique issues in the development of "targeted" antineoplastic pharmaceutical agents.

Maurie Markman.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 15946580     DOI： 10.1007/s11912-005-0043-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  11 in total

1.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

Authors:  M A Cobleigh; C L Vogel; D Tripathy; N J Robert; S Scholl; L Fehrenbacher; J M Wolter; V Paton; S Shak; G Lieberman; D J Slamon
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

Review 2.  STI571: a paradigm of new agents for cancer therapeutics.

Authors:  Michael J Mauro; Michael O'Dwyer; Michael C Heinrich; Brian J Druker
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

3.  Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.

Authors:  V Rusch; J Baselga; C Cordon-Cardo; J Orazem; M Zaman; S Hoda; J McIntosh; J Kurie; E Dmitrovsky
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

4.  Severe acute interstitial pneumonia and gefitinib.

Authors:  Akira Inoue; Yasuo Saijo; Makoto Maemondo; Kazunori Gomi; Yutaka Tokue; Yuichiro Kimura; Masahito Ebina; Toshiaki Kikuchi; Takuya Moriya; Toshihiro Nukiwa
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

5.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

6.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

Review 7.  Targeting the epidermal growth factor receptor in non-small cell lung cancer.

Authors:  Roy S Herbst; Paul A Bunn
Journal:  Clin Cancer Res       Date:  2003-12-01       Impact factor: 12.531

8.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

9.  Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

Authors:  Roy S Herbst; Giuseppe Giaccone; Joan H Schiller; Ronald B Natale; Vincent Miller; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Ira Oliff; James A Reeves; Michael K Wolf; Annetta D Krebs; Steven D Averbuch; Judith S Ochs; John Grous; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

10.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Authors:  Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544
View more
  1 in total

1.  Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.

Authors:  Xian Zhou; Suyu Liu; Edward S Kim; Roy S Herbst; J Jack Lee
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.